Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
Open accessAbstract
Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novel antimitotic cancer therapy recently approved for the treatment of recurrent GBM, based on phase III (EF-11) trial results. The Patient Registry Dataset (PRiDe) is a post-marketing registry of all recurrent GBM patients who received NovoTTF Therapy in a real-world, clinical practice setting in the United States between 2011 and 2013. Data were collected from all adult patients with recurrent GBM who began commercial NovoTTF Therapy in the United States between October 2011 and November 2013. All patients provided written consent before treatment was started. Overall survival (OS) curves were constructed for PRiDe using the Kaplan-Meier method. Median OS in PRiDe was compared for patients stratified by average daily compliance (≥75% v<75% per day) and other prognostic variables. Adverse events were also evaluated. Data from 457 recurrent GBM patients who received NovoTTF Therapy in 91 US cancer centers were analyzed. More patients in PRiDe than the EF-11 trial received NovoTTF Therapy for first recurrence (33% v 9%) and had received prior bevacizumab therapy (55.1% v 19%). Median OS was significantly longer with NovoTTF Therapy in clinical practice (PRiDe data set) than in the EF-11 trial (9.6 v 6.6 months; HR, 0.66; 95% CI, 0.05 to 0.86, P = .0003). One- and 2-year OS rates were more than double for NovoTTF Therapy patients in PRiDe than in the EF-11 trial (1-year: 44% v 20%; 2-year: 30% v 9%). First and second versus third and subsequent recurrences, high Karnofsky performance status (KPS), and no prior bevacizumab use were favorable prognostic factors. No unexpected adverse events were detected in PRiDe. As in the EF-11 trial, the most frequent adverse events were mild to moderate skin reactions associated with application of the NovoTTF Therapy transducer arrays. Results from PRiDe, together with those previously reported in the EF-11 trial, indicate that NovoTTF Therapy offers clinical benefit to patients with recurrent GBM. NovoTTF Therapy has high patient tolerability and favorable safety profile in the real-world, clinical practice setting.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Overall survival outcomes are more favorable in patients with recurrent glioblastoma who maintain higher therapeutic compliance with TTFields therapy.
“This conclusion is supported by clinical observations where overall survival outcomes are more favorable in those patients with recurrent glioblastoma who maintain higher therapeutic compliance with TTFields therapy10.”
From Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells (2015) · cites this paper as [10]
Cites
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · see citing works
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,229 · see citing works
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567 · see citing works
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,383 · see citing works
Riegel, B. J., Moser, D. K., Anker, S. D., Appel, L. J., Dunbar, S. B., Grady, K. L., Gurvitz, M. Z., Havranek, E. P., Lee, C. S., Lindenfeld, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192628 · Cited by 959 · see citing works
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · see citing works
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894 · see citing works
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862 · see citing works
Self-citationDisruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827 · see citing works
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T. F., Perry, J., & Wick, W. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 766 · see citing works
Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Ramirez, Y. P., Weatherbee, J. L., Wheelhouse, R. T., & Ross, A. H. (2013) · Pharmaceuticals · doi:10.3390/ph6121475 · Cited by 236 · see citing works
Kirson, E. D., Schneiderman, R. S., Dbalý, V., Tovaryš, F., Vymazal, J., Itzhaki, A., Mordechovich, D., Gurvich, Z., Shmueli, E., Goldsher, D., et al. (2009) · BMC Medical Physics · doi:10.1186/1756-6649-9-1 · Cited by 224 · see citing works
Mountz, J. M., Ahmed, R., Oborski, M. J., Lieberman, F. S., & Hwang, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s54726 · Cited by 210 · see citing works
The epidemiology of glioma in adults: a "state of the science" review
Morgan, L. L. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou358 · Cited by 199 · see citing works
Tumor treating fields: A new frontier in cancer therapy
Davies, A. M., Weinberg, U., & Palti, Y. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12112 · Cited by 193 · see citing works
Raizer, J. J., Grimm, S. A., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., RADEMAKER, A. W., Renfrow, J. J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 149 · see citing works
Bevacizumab and daily temozolomide for recurrent glioblastoma
Desjardins, A., Reardon, D. A., Sykes, A. D., Marcello, J. E., Herndon, J. E., Bailey, L., Peters, K. B., Friedman, H. S., & Vredenburgh, J. J. (2011) · Cancer · doi:10.1002/cncr.26381 · Cited by 147 · see citing works
Soda, Y., Myskiw, C., Rommel, A., & Verma, I. M. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1019-z · Cited by 141 · see citing works
Anton, K., Baehring, J. M., & Mayer, T. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.04.006 · Cited by 140 · see citing works
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Norden, A. D., Drappatz, J., Muzikansky, A., David, K., Gerard, M., McNamara, M. B., Phan, P., Ross, A., Kesari, S., & Wen, P. Y. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9745-8 · Cited by 135 · see citing works
Advances in the Treatment of Malignant Gliomas
Khasraw, M., & Lassman, A. B. (2010) · Current Oncology Reports · doi:10.1007/s11912-009-0077-4 · Cited by 119 · see citing works
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro, A. M. P., Chan, T. A.-T., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., DeAngelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos295 · Cited by 101 · see citing works
Giladi, M., Schneiderman, R. S., Porat, Y., Munster, M., Itzhaki, A., Mordechovich, D., Cahal, S., Kirson, E. D., Weinberg, U., & Palti, Y. (2014) · Pancreatology · doi:10.1016/j.pan.2013.11.009 · Cited by 98 · see citing works
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma
Nagane, M., Nishikawa, R., Narita, Y., Kobayashi, H., Takano, S., Shinoura, N., Aoki, T., Sugiyama, K., Kuratsu, J., Muragaki, Y., et al. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys121 · Cited by 97 · see citing works
Tumor treating fields: concept, evidence and future
Pless, M., & Weinberg, U. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.583236 · Cited by 78 · see citing works
NovoTTF-100A: a new treatment modality for recurrent glioblastoma
Fonkem, E., & Wong, E. T. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.80 · Cited by 75 · see citing works
Soffietti, R., Trevisan, E., Bertero, L., Cassoni, P., Morra, I., Fabrini, M. G., Pasqualetti, F., Lolli, I. R., Castiglione, A., Ciccone, G., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1317-x · Cited by 72 · see citing works
Schneiderman, R. S., Shmueli, E., Kirson, E. D., & Palti, Y. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-229 · Cited by 65 · see citing works
Greenspoon, J. N., Sharieff, W., Hirte, H. W., Overholt, A., DeVillers, R., Gunnarsson, Þ., & Whitton, A. C. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60358 · Cited by 59 · see citing works
Gutin, P. H., & Wong, E. T. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.122 · Cited by 54 · see citing works
Wong, E. T., Lok, E., Swanson, K. D., Gautam, S., Engelhard, H. H., Lieberman, F. S., Taillibert, S., Ram, Z., & Villano, J. L. (2014) · Cancer Medicine · doi:10.1002/cam4.210 · Cited by 52 · see citing works
Self-citationTransient cavitation in tissues during ultrasonically induced hyperthermia
Sommer, F. G., & Pounds, D. W. (1982) · Medical Physics · doi:10.1118/1.595065 · Cited by 36 · see citing works
Archavlis, E., Tselis, N., Birn, G., Ulrich, P. T., Baltas, D., & Zamboglou, N. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002262 · Cited by 35 · see citing works
Wong, E., Ram, Z., Gutin, P. H., & Ef-Ii, I. R. S. B. (2011) · IRIS · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R., Sherbo, S., Bomzon, Z., Urman, N., Itzhaki, A., et al. (2015) · Scientific Reports · doi:10.1038/srep18046 · Cited by 327 · see citing works
Tumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C. H., Al-Tamimi, Y., & Collis, S. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 319 · see citing works
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Fabian, D., Eibl, M. D. P. G. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V. K., Gonzalez, J., & Palmer, J. D. (2019) · Cancers · doi:10.3390/cancers11020174 · Cited by 241 · see citing works
Toms, S. A., Kim, C., Nicholas, G. A., & Ram, Z. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03057-z · Cited by 183 · see citing works
Tumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177 · see citing works
Central Nervous System Cancers, Version 1.2015
Nabors, B., Portnow, J., Ammirati, M., Baehring, J. M., Brem, H., Brown, P. D., Butowski, N. A., Chamberlain, M. C., Fenstermaker, R. A., Friedman, A. H., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0148 · Cited by 177 · see citing works
Self-citationGiladi, M., Munster, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Blat, R., Zielinska-Chomej, K., Hååg, P., Bomzon, Z., Kirson, E. D., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0941-6 · Cited by 159 · see citing works
Virtual Human Models for Electromagnetic Studies and Their Applications
Makarov, S. N., Noetscher, G. M., Yanamadala, J., Piazza, M. W., Louie, S., Prokop, A., Nazarian, A., & Nummenmaa, A. R. (2017) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2722420 · Cited by 157 · see citing works
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137 · see citing works
Wenger, C., Miranda, P. C., Salvador, R., Thielscher, A., Bomzon, Z., Giladi, M., Mrugala, M. M., & Korshoej, A. R. (2018) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2765282 · Cited by 129 · see citing works
Self-citationWenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/18/7339 · Cited by 121 · see citing works
Mehta, M. P., Wen, P. Y., Nishikawa, R., Reardon, D. A., & Peters, K. B. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.005 · Cited by 109 · see citing works
Tumor Treating Fields in the Management of Patients with Malignant Gliomas
Ghiaseddin, A. P., Shin, D. H., Melnick, K. F., & Tran, D. D. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00773-5 · Cited by 105 · see citing works
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 103 · see citing works
Permeabilizing Cell Membranes with Electric Fields
Aguilar, A. A., Ho, M. C., Chang, E., Carlson, K. W., Natarajan, A., Marciano, T., Bomzon, Z., & Patel, C. B. (2021) · Cancers · doi:10.3390/cancers13092283 · Cited by 76 · see citing works
Wenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.11.042 · Cited by 76 · see citing works
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
Guo, X., Yang, X., Wu, J., Yang, H., Li, Y., Li, J., Liu, Q., Chen, W., Xing, H., Liu, P., et al. (2022) · Cancers · doi:10.3390/cancers14153669 · Cited by 73 · see citing works
Kesari, S., Ram, Z., & on behalf of EF-14 Trial Investigators (2017) · CNS Oncology · doi:10.2217/cns-2016-0049 · Cited by 72 · see citing works
Korshoej, A. R., Hansen, F. L., Thielscher, A., von Öettingen, G., & Sørensen, J. C. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179214 · Cited by 71 · see citing works
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Burri, S. H., Gondi, V., Brown, P. D., & Mehta, M. P. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000395 · Cited by 71 · see citing works
Lacouture, M. E., Anadkat, M. J., Ballo, M. T., IWAMOTO, F. M., Jeyapalan, S. A., Rocca, R. V. L., Schwartz, M. A., Serventi, J. N., & Glas, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01045 · Cited by 70 · see citing works
Electrotherapies for Glioblastoma
Jenkins, E. P. W., Finch, A., Gerigk, M., Triantis, I. F., Watts, C., & Malliaras, G. G. (2021) · Advanced Science · doi:10.1002/advs.202100978 · Cited by 68 · see citing works
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 70 · see citing works
Swanson, K. D., Lok, E., & Wong, E. T. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0606-5 · Cited by 65 · see citing works
Kessler, A. F., Frömbling, G. E., Gross, F., Hahn, M., Dzokou, W., Ernestus, R.-I., Löhr, M., & Hagemann, C. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0079-9 · Cited by 64 · see citing works
Korshoej, A. R., Hansen, F. L., Mikic, N., von Öettingen, G., Sørensen, J. C. H., & Thielscher, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201957 · Cited by 62 · see citing works
Shi, W., Blumenthal, D. T., Oberheim Bush, N. A., Kebir, S., Lukas, R. V., Muragaki, Y., Zhu, J.-J., & Glas, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03540-6 · Cited by 61 · see citing works
Self-citationRecent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma
Khagi, S., Kotecha, R. R., Gatson, N. T., Jeyapalan, S. A., Abdullah, H. I., Avgeropoulos, N. G., Batzianouli, E., Giladi, M., Lustgarten, L., & Goldlust, S. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae227 · Cited by 56 · see citing works
Progress and prospect in tumor treating fields treatment of glioblastoma
Liu, S., Shi, W., Zhao, Q., Zheng, Z., Liu, Z., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111810 · Cited by 54 · see citing works
Korshoej, A. R., Saturnino, G. B., Rasmussen, L. K., von Öettingen, G., Sørensen, J. C. H., & Thielscher, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164051 · Cited by 54 · see citing works
Use of bevacizumab in recurrent glioblastoma
Ghiaseddin, A. P., & Peters, K. B. (2015) · CNS Oncology · doi:10.2217/cns.15.8 · Cited by 54 · see citing works
Tumor treating fields: a new approach to glioblastoma therapy
Rick, J. W., Chandra, A., & Aghi, M. K. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2768-x · Cited by 52 · see citing works
Rogers, J. R., Lee, J., Zhou, Z., Cheung, Y. K., Hripcsak, G. M., & Weng, C. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa224 · Cited by 46 · see citing works
Kinzel, A., Ambrogi, M., Varshaver, M., & Kirson, E. D. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918825449 · Cited by 45 · see citing works
Yang, Y., Hu, X., Liu, Y., Ouyang, B., Zhang, J., Jin, H., Yu, Z., Liu, R., Li, Z., Jiang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5023 · Cited by 45 · see citing works
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45 · see citing works
Benson, L. M. (2018) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2018.03.005 · Cited by 41 · see citing works
Rehman, A. A., Elmore, K. B., & Mattei, T. A. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14742 · Cited by 40 · see citing works
Acceptance and compliance of TTFields treatment among high grade glioma patients
Onken, J., Staub‐Bartelt, F., Vajkoczy, P., & Misch, M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2858-9 · Cited by 38 · see citing works
Ram, Z., Kim, C., Hottinger, A. F., Idbaïh, A., Nicholas, G. A., & Zhu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671972 · Cited by 37 · see citing works
Self-citationKorshoej, A. R., Lukacova, S., Lassen–Ramshad, Y., Rahbek, C., Severinsen, K. E., Guldberg, T. L., Mikic, N., Jensen, M. H., Cortnum, S., von Öettingen, G., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa121 · Cited by 36 · see citing works
An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
Wong, E. T., Lok, E., & Swanson, K. D. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0353-5 · Cited by 35 · see citing works
Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis
Regev, O., Merkin, V., Blumenthal, D. T., Melamed, I., & Kaisman‐Elbaz, T. (2021) · Neuro-Oncology Practice · doi:10.1093/nop/npab026 · Cited by 34 · see citing works
Campana, L. G., DAUD, A. I., Lancellotti, F., Arroyo, J. P., Davalos, R. V., Prata, C. D., & Gehl, J. (2023) · Cancers · doi:10.3390/cancers15133340 · Cited by 33 · see citing works
In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
Blatt, R., Davidi, S., Munster, M., Shteingauz, A., Cahal, S., Zeidan, A., Marciano, T., Bomzon, Z., Haber, A., Giladi, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670809 · Cited by 32 · see citing works
Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1
Fan, H., Yuan, R., Cheng, S., Xiong, K., Xingen, Z., & Zhang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.050 · Cited by 31 · see citing works
Medical Device Advances in the Treatment of Glioblastoma
Foo, C. Y., Munir, N., Kumaria, A., Akhtar, Q., Bullock, C. J., Narayanan, A., & Fu, R. Z. (2022) · Cancers · doi:10.3390/cancers14215341 · Cited by 31 · see citing works
Skin toxicities associated with tumor treating fields: case based review
Lukas, R. V., Julian, K. L., Wong, E. T., & Villano, J. L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2612-8 · Cited by 31 · see citing works
Self-citationShams, S., & Patel, C. B. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac047 · Cited by 30 · see citing works
Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations
Lok, E., Swanson, K. D., & Wong, E. T. (2015) · Expert Review of Medical Devices · doi:10.1586/17434440.2015.1086641 · Cited by 30 · see citing works
Gkika, E., Grosu, A., Macarulla, T. M., Gracián, A. C., Brunner, T. B., Schultheiß, M., Pazgan−Simon, M., Seufferlein, T. T. W., & Touchefeu, Y. (2022) · Cancers · doi:10.3390/cancers14061568 · Cited by 29 · see citing works
Alternating Electric Fields for the Treatment of Glioblastoma
Sampson, J. H. (2015) · JAMA · doi:10.1001/jama.2015.16701 · Cited by 29 · see citing works
Shiba, H., Takeuchi, K., Hiramatsu, R., Furuse, M., Nonoguchi, N., Kawabata, S., Kuroiwa, T., Kondo, N., Sakurai, Y., Suzuki, M., et al. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.oa.2018-0111 · Cited by 28 · see citing works
How We Treat Recurrent Glioblastoma Today and Current Evidence
Barbosa, C. C., & Marques, D. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0834-y · Cited by 27 · see citing works
Liu, S., Zhao, Q., Shi, W., Zheng, Z., Liu, Z., Meng, L., Dong, L., & Jiang, X. M. (2020) · Journal of Cancer · doi:10.7150/jca.51107 · Cited by 27 · see citing works
Current and promising treatment strategies in glioma
Śledzińska, P., Bebyn, M. G., Furtak, J., Koper, A., & Koper, K. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0060 · Cited by 27 · see citing works
Chen, C., Xu, H., Song, K., Zhang, Y., Zhang, J., Wang, Y., Sheng, X., Chen, L., & Qin, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195855 · Cited by 25 · see citing works
Nishikawa, R., Yamasaki, F., Arakawa, Y., Muragaki, Y., Narita, Y., Tanaka, S., Yamaguchi, S., Mukasa, A., & Kanamori, M. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad001 · Cited by 24 · see citing works
A systematic review of tumor treating fields therapy for high-grade gliomas
Shah, P. P., White, T., Khalafallah, A. M., Romo, C. G., Price, C. L., & Mukherjee, D. R. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03563-z · Cited by 23 · see citing works
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
Liu, Y., Strawderman, M. S., Warren, K., Richardson, M., Serventi, J. N., Mohile, N. A., Milano, M. T., & Walter, K. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14597 · Cited by 22 · see citing works
She, L., Gong, X., Su, L., & Liu, C. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1042888 · Cited by 22 · see citing works
Raman, F., Scribner, E. Y., Saut, O., Wenger, C., Colin, T., & Fathallah‐Shaykh, H. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146617 · Cited by 22 · see citing works
Zhu, J., Goldlust, S. A., Kleinberg, L. R., Honnorat, J., Bush, N. A. O., & Ram, Z. (2022) · Discover Oncology · doi:10.1007/s12672-022-00555-5 · Cited by 21 · see citing works
Self-citationAnsstas, G., & Tran, D. D. (2016) · Case Reports in Neurology · doi:10.1159/000442196 · Cited by 21 · see citing works
Current clinical management of patients with glioblastoma
Lowe, S. R., Bhat, K., & Olar, A. (2019) · Cancer Reports · doi:10.1002/cnr2.1216 · Cited by 20 · see citing works
Mikic, N., Poulsen, F. R., Kristoffersen, K. B., Laursen, R. J., Guldberg, T. L., Skjøth‐Rasmussen, J., Wong, E. T., Møller, S., Dahlrot, R. H., Sørensen, J. C. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08709-4 · Cited by 20 · see citing works
The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV
Krigers, A., Pinggera, D., Demetz, M., Kornberger, L.-M., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.900377 · Cited by 20 · see citing works
Temperature and Impedance Variations During Tumor Treating Fields (TTFields) Treatment
Gentilal, N., Abend, E., Naveh, A., Marciano, T., Balin, I., Telepinsky, Y., & Miranda, P. C. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.931818 · Cited by 19 · see citing works
Novel therapeutic strategies in glioma targeting glutamatergic neurotransmission
Kumaria, A., & Ashkan, K. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148515 · Cited by 18 · see citing works
Berger, T. R., & Wong, E. T. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.02.04 · Cited by 18 · see citing works
Kazemi, K., Amini, A., Omidifar, N., Aghaabdollahian, S., Raee, M. J., & Gholami, A. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00317-2 · Cited by 18 · see citing works
Skull modulated strategies to intensify tumor treating fields on brain tumor: a finite element study
Yang, X., Liu, P., Xing, H., Wen, X., Wang, Y., Hu, C., Li, L., & Ma, W. (2022) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-022-01580-7 · Cited by 17 · see citing works
Olatunji, G. D., Aderinto, N., Oluwakorede, A. T., Kokori, E., Akinmoju, O. D., Yusuf, I. A., Olusakin, T. C., & Muzammil, M. A. (2023) · Medicine · doi:10.1097/md.0000000000036421 · Cited by 17 · see citing works
Mrugała, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04682-7 · Cited by 17 · see citing works
O’Connell, D., Shen, V., Loudon, W. G., & Bota, D. A. (2016) · CNS Oncology · doi:10.2217/cns-2016-0018 · Cited by 17 · see citing works
Tumor-Treating Fields Therapy for Pediatric Brain Tumors
Makimoto, A., Nishikawa, R., Terashima, K., Kurihara, J., Fujisaki, H., Ihara, S., Morikawa, Y., & Yuza, Y. (2021) · Neurology International · doi:10.3390/neurolint13020015 · Cited by 17 · see citing works
Tumor Treating Fields in Neuro-Oncological Practice
Mrugała, M. M., Ruzevick, J., Złomańczuk, P., & Lukas, R. V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0611-8 · Cited by 16 · see citing works
Kütük, T., Appel, H. R., Avendano, M. C., Albrecht, F., Kaywin, P., Ramos, S., Suarez-Murias, M., Mehta, M. P., & Kotecha, R. R. (2022) · Cancers · doi:10.3390/cancers14082020 · Cited by 16 · see citing works
Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.
Lee, W. S., Seo, S., Chung, H. K., Park, J. W., Kim, J.-K., & Kim, E. H. (2021) · PubMed Central · Cited by 14 · see citing works
Smothers, A. R., Henderson, J. R., O’Connell, J. J., Stenbeck, J. M., Dean, D. M. D., Harvey, T. G., & Booth, B. W. (2023) · Discover Oncology · doi:10.1007/s12672-023-00647-w · Cited by 14 · see citing works
Tumor treating fields: narrative review of a promising treatment modality for cancer
Kütük, T., Atak, E., Rosa, A. L., Kotecha, R. R., Mehta, M. P., & Chuong, M. D. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-82 · Cited by 12 · see citing works
Acoustoelectric materials & devices in biomedicine
Zhang, X., Zhang, Y., Zhang, J., Shang, J., Lin, L., Liu, Q., & An, Q. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149314 · Cited by 13 · see citing works
Goldman, S., Margol, A., Hwang, E. I., Tanaka, K., Suchorska, B., Crawford, J. R., & Kesari, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958637 · Cited by 13 · see citing works
Chronic inflammation: is it the driver or is it paving the road for malignant transformation?
Afrasiabi, K., Zhou, Y., & Fleischman, A. G. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.64 · Cited by 12 · see citing works
Optune®: Practical Nursing Applications
Murphy, J., Bowers, M. E., & Barron, L. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.s1.14-19 · Cited by 12 · see citing works
Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis
Magouliotis, D. E., Asprodini, E. K., Svokos, K. A., Tasiopoulou, V. S., Svokos, A. A., & Toms, S. A. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3536-6 · Cited by 12 · see citing works
Oberheim-Bush, N. A., Shi, W., McDermott, M. W., Grote, A., Stindl, J., & Lustgarten, L. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04033-4 · Cited by 12 · see citing works
Taillibert, S., Rhun, É. L., & Chamberlain, M. C. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000250 · Cited by 11 · see citing works
Bosnyák, E., Barger, G. R., Michelhaugh, S. K., Robinette, N. L., Amit-Yousif, A. J., Mittal, S., & Juhász, C. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001942 · Cited by 11 · see citing works
Wenger, C., Hershkovich, H. S., Tempel-Brami, C., Giladi, M., & Bomzon, Z. (2019) · Springer eBooks · doi:10.1007/978-3-030-21293-3_20 · Cited by 11 · see citing works
Kumaria, A. (2021) · British Journal of Neurosurgery · doi:10.1080/02688697.2021.1886242 · Cited by 11 · see citing works
Li, S., Dong, J., Wang, X., Meng, X., Jiang, C., & Cai, J. (2022) · Chinese Neurosurgical Journal · doi:10.1186/s41016-022-00294-0 · Cited by 11 · see citing works
Szász, A. M., Arrojo, E. E., Fiorentini, G., Herold, M., Herold, Z., Sarti, D., & Dank, M. (2023) · Cancers · doi:10.3390/cancers15030880 · Cited by 10 · see citing works
Wang, J., Du, Q., Chen, J., Liu, J., Gu, Z., Wang, X., Zhang, A., Gao, S., Shao, A., Zhang, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1345190 · Cited by 10 · see citing works
Tumor Treating Fields and Combination Therapy in Management of Brain Oncology
Liu, R. N., Huang, J. H., Qi, X., Pan, Y., Wu, E., & Nizamutdinov, D. (2025) · Cancers · doi:10.3390/cancers17071211 · Cited by 10 · see citing works
Li, X., Jia, Z., & Yan, Y. (2022) · Acta Neurochirurgica · doi:10.1007/s00701-022-05192-z · Cited by 10 · see citing works
Zygogianni, A. G., Protopapa, M., Kougioumtzopoulou, A., Simopoulou, F., Nikoloudi, S., & Kouloulias, V. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1831-6 · Cited by 10 · see citing works
Smothers, A. R., Henderson, J. R., O’Connell, J. J., Stenbeck, J. M., Dean, D. M. D., & Booth, B. W. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02959-x · Cited by 9 · see citing works
Kim, E. H., Lee, W. S., & Oh, H. K. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1853 · Cited by 9 · see citing works
Barkhoudarian, G., Badruddoja, M., Blondin, N. A., Chowdhary, S. A., Cobbs, C., Duic, J. P., Flores, J. P., Fonkem, E., McClay, E. F., Nabors, B., et al. (2023) · CNS Oncology · doi:10.2217/cns-2022-0016 · Cited by 9 · see citing works
- Authors
- Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., & Butowski, N.
- Affiliations
- University of Illinois Hospital & Health Sciences System (US)
- Houston Methodist (US)
- The Ohio State University (US)
- University of Illinois Chicago (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 41
- Pages
- S4-S13
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W1994913111
- Cited by
- 152
- References
- 36
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 25 · 2021: 12 · 2020: 11 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 13
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Seminars in Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- overall survival, medication adherence, bevacizumab, prognostic factors, Karnofsky performance status, adverse events, skin reactions, real-world clinical practice, first recurrence
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Combined Modality Therapy, Electric Stimulation Therapy, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Practice Patterns, Physicians', Prognosis, Registries, Survival Rate, Clinical Trials, Phase III as Topic, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
